The improvement in EPS for Novavax suggests cost management or operational efficiency gains, which could be positive for investor sentiment. However, the significant drop in sales year-over-year indicates potential challenges in revenue generation or market demand, which could concern investors. The mixed financial performance makes the short-term impact on the stock price uncertain, hence a neutral score.